Andres Lopez,Pau Abrisqueta
Andres Lopez
Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large neoplastic cells, most of them resembling plasmablasts that have a CD20-negative phenotype. Although initially described as being associated with HIV, over t...
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia [0.03%]
近年来B细胞急性淋巴细胞白血病的生物和治疗学进展
Mehrdad Hefazi,Mark R Litzow
Mehrdad Hefazi
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult...
Current understanding of the role and regulation of miRNAs in Burkitt lymphoma [0.03%]
关于miRNA在Burkitt淋巴瘤中作用和调控的当前认识
Alessandro Davide Videtta,Valeria Malagnino,Giulia De Falco
Alessandro Davide Videtta
Since its discovery in 1958, Burkitt lymphoma (BL) has been extensively studied and has become a model for tumorigenesis, but its pathogenesis has not been completely explained and understood yet. The aim of this review was to summarize the...
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions [0.03%]
冒烟型多发性骨髓瘤的流行率及目前关于治疗决策的研究证据指导原则
Agnieszka Blum,Despina Bazou,Peter O&#x;Gorman
Agnieszka Blum
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined signific...
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era [0.03%]
正电子发射断层扫描时代化疗后晚期霍奇金淋巴瘤的结局和复发模式
Carminia Lapuz,Anoop K Enjeti,Peter C O&#x;Brien et al.
Carminia Lapuz et al.
Background: This study evaluated relapse patterns and survival in advanced Hodgkin lymphoma (HL) patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) with positron emission tomography (PET) use...
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [0.03%]
用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的 Ponatinib 的用药指征及前景展望
Theodora Anagnostou,Mark R Litzow
Theodora Anagnostou
Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are eit...
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects [0.03%]
颗粒细胞浆样树突状细胞肿瘤的挑战和未来前景
Amy M Trottier,Sonia Cerquozzi,Carolyn J Owen
Amy M Trottier
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to diagnose and treat. BPDCN typically presents with nonspecific cutaneous lesions with or without extra-cutaneous manifestatio...
Impact of obinutuzumab alone and in combination for follicular lymphoma [0.03%]
奥英利珠单抗单药及联合治疗滤泡性淋巴瘤的影响
Maryam Sarraf Yazdy,Bruce D Cheson
Maryam Sarraf Yazdy
Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory...
Complications and management of coagulation disorders in leukemia patients [0.03%]
急性白血病凝血功能障碍的并发症及处理
Deepesh Lad,Arihant Jain,Subhash Varma
Deepesh Lad
Patients with leukemia are predisposed to various coagulation abnormalities. Thrombosis and bleeding continue to be a major cause of morbidity and mortality in leukemias. The pathophysiology of these disorders is unique, and not only the di...